• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

128.63 -1.47 (-1.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,080,171
Open 129.45
Bid (Size) 120.12 (100)
Ask (Size) 135.00 (100)
Prev. Close 130.10
Today's Range 127.16 - 130.34
52wk Range 84.23 - 160.18
Shares Outstanding 100,100,000
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗
February 19, 2026
This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗
February 19, 2026
Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
-8.5%
-8.5%
1 Month
-5.5%
-5.5%
3 Month
-8.9%
-8.9%
6 Month
-4.0%
-4.0%
1 Year
+8.0%
+8.0%

More News

Read More
News headline image
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗
February 19, 2026
Via The Motley Fool
Neurocrine Biosciences Inc (NASDAQ:NBIX) Fits the GARP Strategy with Strong Growth and Reasonable Valuation ↗
February 17, 2026
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Screens as a Compelling Value Investment ↗
February 13, 2026
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Reports Q4 2025 Earnings Miss Amid Strong Annual Sales Growth ↗
February 11, 2026
Via Chartmill
Topics Earnings
News headline image
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗
February 19, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider ↗
February 19, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Neurocrine (NBIX) Q4 2025 Earnings Call Transcript ↗
February 11, 2026
Via The Motley Fool
Topics Earnings
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup ↗
January 31, 2026
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Prime Affordable Growth Stock ↗
January 23, 2026
Via Chartmill
Neurocrine Biosciences Inc. (NASDAQ:NBIX) Presents a Compelling Value Investment Case ↗
January 07, 2026
Via Chartmill
CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial ↗
January 05, 2026
Via Stocktwits
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Offers a Prime Example of Growth at a Reasonable Price ↗
December 16, 2025
Via Chartmill
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with Bullish Technical Setup ↗
December 04, 2025
Via Chartmill
News headline image
Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗
December 03, 2025
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗
December 03, 2025
Via The Motley Fool
News headline image
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗
December 03, 2025
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Neurocrine (NBIX) Q3 2025 Earnings Call Transcript ↗
November 27, 2025
Via The Motley Fool
Topics Earnings
News headline image
Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗
November 26, 2025
Via Investor's Business Daily
Topics Economy Government
News headline image
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗
November 18, 2025
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
November 18, 2025
Via The Motley Fool
News headline image
High Growth Momentum Stock NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Shows Strong Earnings Acceleration ↗
November 13, 2025
Via Chartmill
News headline image
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile ↗
November 11, 2025
Via Benzinga
News headline image
Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
November 11, 2025
Via Benzinga

Frequently Asked Questions

Is Neurocrine Biosciences, Inc. - Common Stock publicly traded?
Yes, Neurocrine Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Neurocrine Biosciences, Inc. - Common Stock trade on?
Neurocrine Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Neurocrine Biosciences, Inc. - Common Stock?
The ticker symbol for Neurocrine Biosciences, Inc. - Common Stock is NBIX on the Nasdaq Stock Market
What is the current price of Neurocrine Biosciences, Inc. - Common Stock?
The current price of Neurocrine Biosciences, Inc. - Common Stock is 128.63
When was Neurocrine Biosciences, Inc. - Common Stock last traded?
The last trade of Neurocrine Biosciences, Inc. - Common Stock was at 02/20/26 04:00 PM ET
What is the market capitalization of Neurocrine Biosciences, Inc. - Common Stock?
The market capitalization of Neurocrine Biosciences, Inc. - Common Stock is 12.88B
How many shares of Neurocrine Biosciences, Inc. - Common Stock are outstanding?
Neurocrine Biosciences, Inc. - Common Stock has 13B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap